Echo Pharmaceuticals in Weesp is dedicated to develop novel medicines, with a special focus on isolated cannabinoids as the active ingredient, and drug delivery technologies in order to improve the quality of life of patients all over the world. The main product, Namisol® is set to be registered for a number of indications, including Multiple Sclerosis (MS), Alzheimer’s Disease, and Chronic Pain. Namisol is currently in phase II of clinical development. The second product, Arvisol®, is currently in a phase I trial. The therapeutic area is Schizophrenia.